Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort

• Published in: AIDS research and therapy 2012-06, Vol.9 (1), p.19-19
• Main Authors: Chua, Arlene C, Llorin, Ryan M, Lai, Kelvin, Cavailler, Philippe, Law, Hwa Lin
• Format: Article
• Language: English
• Subjects: AIDS treatment; Antiretrovirals; Drug therapy; Health aspects; Highly active antiretroviral therapy; Kidney; Kidney diseases; Medical research; Medicine, Experimental; Risk factors; Safety and security measures; Short Report; Tenofovir
• ISSN: 1742-6405; 1742-6405
• DOI: 10.1186/1742-6405-9-19

Tenofovirdisoproxilfumarate (TDF) is a nucleotide analogue widely recommended in international HIV treatment guidelines. The association of TDF and renal dysfunction has remained an area of interest. We conducted a retrospective review of all patients on TDF from July 2007 to December 2009 in our institution and evaluated their renal function. Absolute change of creatinine clearance (CLCr) using Cockroft-Gault equation from baseline was calculated at 6, 12, 18 and 24 months. Overall, 226 patients were included in the study. Ninety percent were male. The median age was 46 yrs old (23-82), median weight was 60 kg (IQR 53.75-68), median CD4 count was 127 cells/mm3 (IQR 38-258) and median CLCr 82.7 mL/min (IQR 71.4-101.7) on initiation of TDF. The median decline of CLCr from baseline was -3.9 ml/min (IQR -12.3 to 7.6), and -3.6 ml/min (IQR -12.4 to 6.7) at 12 (n = 102), 24 months (n = 75) respectively. Eighteen of 226 patients had a decline in renal function to